Skip to main content
Scroll to Continue

Recommended Articles

Tumor cell target

Kadcyla (Trastuzumab Emtansine) in HER2-Positive Early Breast Cancer with Residual Invasive Disease

Long-term results demonstrate improved survival and sustained improvement in invasive disease-free survival for study patients treated with Kadcyla vs Herceptin

DNA focus

Lumakras (Sotorasib) in combination with Vectibix (Panitumumab) FDA Approved for Metastatic Colorectal Cancer with KRAS G12C Mutation

CODEBreaK 300 study demonstrated combination more than doubled progression-free survival compared to physician’s choice of standard of care